The Economics Of System Integration: Toward An Evolutionary Interpretation.

--

Boosted Top Quark Pair Production in Soft Collinear Effective Theory

We review a Soft Collinear Effective Theory approach to the study of factorization and resummation of QCD effects in top-quark pair production. In particular, we consider differential cross sections such as the top-quark pair invariant mass distribution and the top-quark transverse momentum and rapidity distributions. Furthermore, we focus our attention on the large invariant mass and large transverse momentum kinematic regions, characteristic of boosted top quarks. We discuss the factorization of the differential cross section in the double soft gluon emission and small top-quark mass limit, both in Pair Invariant Mass (PIM) and One Particle Inclusive (1PI) kinematics. The factorization formulas can be employed in order to implement the simultaneous resummation of soft emission and small mass effects up to next-to-next-to-leading logarithmic accuracy. The results are also used to construct improved next-to-next-to-leading order approximations for the differential cross sections.Comment: 6 pages. Proceedings of the Second Annual Conference on Large Hadron Collider Physics (LHCP 2014), Columbia University, New York, June 2-7, 201

The economics of system integration: Toward an evolutionary interpretation

In this work we propose some elements of an interpretation of the dynamics of system integration (and disintegration) in the case of complex product systems (CoPS henceforth). The latter include a significant subset of capital goods such as most mobile communication systems, many military systems, corporate information technology networks, train engines

Contacting authors to retrieve individual patient data study protocol for a randomized controlled trial

BACKGROUND: Individual patient data (IPD) meta-analysis is considered the "gold standard" for exploring the effectiveness of interventions in different subgroups of patients. However, obtaining IPD is time-consuming and contact with the researchers responsible for the original trials is usually required. To date, there are no studies evaluating different strategies to optimize the process for retrieval of IPD from such researchers. Our aim is to examine the impact of providing incentives to the researchers responsible for the trials eligible for a meta-analysis to submit their IPD.METHODS/DESIGN: We updated our previously published systematic reviews for type 1 diabetes mellitus comparing long- and intermediate-acting insulin regimens (from January 2013 to June 2015) and for Alzheimer's dementia comparing cognitive enhancers (from January 2015 to May 2015). Eligible were randomized controlled trials (RCTs) fulfilling the eligibility criteria of the systematic reviews. We will randomly allocate authors of the reports of these RCTs into an intervention or control group. Those allocated to the intervention group will be contacted by email, mail, and phone, and will be asked to provide the IPD from their RCT and will be given a financial incentive. Those allocated to the control group will be contacted by email, mail, and phone, but will not receive a financial incentive. Our primary outcome will be the proportion of authors who provide the IPD. The secondary outcomes will be the time to return the dataset (defined as the period between the information request and the authors' response with the dataset), and completeness of data. We will compare the response rates in the two groups using the odds ratio and the corresponding 95 % confidence interval. We will also use binary logistic regression and cox regression analyses to examine whether different RCT characteristics, such as study size and sponsor information, influence the probability of providing IPD and the time needed to share the data.DISCUSSION: This study will determine whether a financial incentive affects response rates when seeking IPD from the original researchers. We will disseminate our findings in an open access scientific journal and present results at national and international conferences.TRIAL REGISTRATION: This trial is registered in Clinical Trials.gov, ID number NCT02569411 . Date of registration 5 October 2015.</p